VIVA Biotech Holdings 주식 주식분석 | 주식가격 | 뉴스 | 1873.HK | KYG9390W1015 | A2PH5Q

날짜	VIVA Biotech Holdings 주식 가격
	0.85 undefined
	0.89 undefined
	0.88 undefined
	0.91 undefined
	0.94 undefined
	0.86 undefined
	0.83 undefined
	0.84 undefined
	0.85 undefined
	0.84 undefined
	0.81 undefined
	0.80 undefined
	0.77 undefined
	0.82 undefined
	0.85 undefined
	0.88 undefined
	0.88 undefined
	0.97 undefined
	1.08 undefined
	0.98 undefined

날짜	VIVA Biotech Holdings 매출	VIVA Biotech Holdings EBIT	VIVA Biotech Holdings 이익
2025e	3.43 조. undefined	487.27 백만 undefined	519.94 백만 undefined
2024e	3.03 조. undefined	401.91 백만 undefined	439.11 백만 undefined
2023	2.16 조. undefined	234.71 백만 undefined	-116.11 백만 undefined
2022	2.38 조. undefined	295.38 백만 undefined	-528.48 백만 undefined
2021	2.1 조. undefined	260.11 백만 undefined	287.55 백만 undefined
2020	696.96 백만 undefined	89.5 백만 undefined	-386.88 백만 undefined
2019	323.06 백만 undefined	60.14 백만 undefined	265.87 백만 undefined
2018	210.03 백만 undefined	54.56 백만 undefined	90.55 백만 undefined
2017	148.25 백만 undefined	57.43 백만 undefined	76.26 백만 undefined
2016	96.49 백만 undefined	29.41 백만 undefined	24.47 백만 undefined

	매출	EBIT	이익
2016	96.49 백만 CNY	29.41 백만 CNY	24.47 백만 CNY
2017	148.25 백만 CNY	57.43 백만 CNY	76.26 백만 CNY
2018	210.03 백만 CNY	54.56 백만 CNY	90.55 백만 CNY
2019	323.06 백만 CNY	60.14 백만 CNY	265.87 백만 CNY
2020	696.96 백만 CNY	89.5 백만 CNY	-386.88 백만 CNY
2021	2.1 조. CNY	260.11 백만 CNY	287.55 백만 CNY
2022	2.38 조. CNY	295.38 백만 CNY	-528.48 백만 CNY
2023	2.16 조. CNY	234.71 백만 CNY	-116.11 백만 CNY
2024e	3.03 조. CNY	401.91 백만 CNY	439.11 백만 CNY
2025e	3.43 조. CNY	487.27 백만 CNY	519.94 백만 CNY

2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e
0.1	0.15	0.21	0.32	0.7	2.1	2.38	2.16	3.03	3.43
-	54.17	41.89	53.81	115.48	202.30	13.07	-9.42	40.46	13.25
56.25	58.11	50.00	47.99	43.68	30.89	34.26	34.25	-	-
54	86	105	155	304	650	815	738	0	0
29	57	54	60	89	260	295	234	401	487
30.21	38.51	25.71	18.58	12.79	12.36	12.40	10.86	13.25	14.21
24	76	90	265	-386	287	-528	-116	439	519
-	216.67	18.42	194.44	-245.66	-174.35	-283.97	-78.03	-478.45	18.22
1.15	1.16	1.19	1.48	1.57	1.97	1.92	1.94	0	0
-	-	-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022	2023

0.01	0.03	0.16	0.93	2.36	0.8	0.68	1.04
19.74	28.64	51.46	57.51	313.47	423.01	432.49	394.55
22.8	4.4	6.79	80.51	89.6	108.89	72.9	148.98
1.01	3.32	4.9	8.53	164.75	231.72	326.03	259.71
8.19	13.82	22.46	14.17	425.78	419.22	428.83	191.36
0.07	0.08	0.24	1.09	3.35	1.98	1.94	2.03
0.02	0.03	0.07	0.16	0.74	1.72	1.94	1.65
0.01	0.08	0.21	0.63	0.92	1.25	1.05	1.15
0	3.69	3.37	5.41	15.38	16.12	6.43	5.25
0	0	0	0	469.46	531.44	476.06	420.67
0	0	0	0	1.85	2.16	2.16	2.16
3.19	3.29	7.89	14.89	808.43	386.36	359.15	28.44
0.04	0.12	0.29	0.8	4.8	6.06	5.98	5.42
0.1	0.2	0.53	1.9	8.15	8.04	7.92	7.45

120	120	164	261	323	326	326	367
0.01	0.01	0.05	1.3	3.65	3.64	3.64	3.87
62.79	139.05	204.03	478.23	-225.41	60.86	-296.68	-1.19
0	0	0	0.23	383.84	349.87	398.77	-50.78
0	0	0	0	0	0	0	0
0.08	0.15	0.25	1.78	3.81	4.05	3.74	3.82
1.58	3.77	4.69	7.55	295.7	281.05	326.13	245.76
4.87	6.8	17.77	20.99	147.68	105.85	140.37	133.35
9.2	13.84	19.51	19.43	125.32	300.96	289.88	195.72
0	12.11	0	0	0	0	0	6.91
0	0	0	0.02	0.17	0.24	1.92	0.95
0.02	0.04	0.04	0.07	0.74	0.93	2.67	1.53
0	0	0	0.02	2.8	2.42	0.91	0.95
0	0	3.12	8.16	119.18	117.73	92.2	69.19
0.01	0.01	0.23	0.02	0.74	0.67	0.64	1.21
0.01	0.01	0.24	0.05	3.66	3.2	1.64	2.23
0.03	0.05	0.28	0.12	4.4	4.13	4.32	3.76
0.1	0.2	0.53	1.9	8.21	8.18	8.06	7.58

2016	2017	2018	2019	2020	2021	2022
28	86	105	280	-356	347	-459
3	5	9	34	69	153	185
0	0	0	0	0	0	0
-10	-16	-25	-20	-90	-306	-98
0	-47	-78	-248	409	-116	758
0	0	0	0	11	71	72
2	6	4	16	17	45	80
21	27	12	46	32	77	386
-7	-18	-46	-56	-592	-565	-249
-19	-9	-69	-290	-3,838	-868	-372
-12	9	-23	-233	-3,245	-303	-123
0	0	0	0	0	0	0
0	0	0	-0.02	4.46	-0.42	-0.07
0	0	0.2	1.21	0.92	-0.13	0
0	0	0.18	0.98	5.31	-0.65	-0.14
-	-	-19.00	-76.00	-17.00	-84.00	-70.00
0	0	0	-135	-51	-16	0
0	0.02	0.13	0.75	1.4	-1.51	-0.12
13.78	8.97	-34.79	-10.18	-560.46	-487.35	136.51
0	0	0	0	0	0	0

VIVA Biotech Holdings 브루토마진	VIVA Biotech Holdings 이익 마진	VIVA Biotech Holdings EBIT-마진	VIVA Biotech Holdings 이익 마진
2025e	34.26 %	14.21 %	15.17 %
2024e	34.26 %	13.28 %	14.51 %
2023	34.26 %	10.89 %	-5.39 %
2022	34.28 %	12.41 %	-22.21 %
2021	30.94 %	12.36 %	13.67 %
2020	43.74 %	12.84 %	-55.51 %
2019	48.25 %	18.61 %	82.3 %
2018	50.21 %	25.98 %	43.11 %
2017	58.14 %	38.74 %	51.44 %
2016	56.11 %	30.48 %	25.36 %

	브루토마진	EBIT-마진	이익 마진
2016	56.11 %	30.48 %	25.36 %
2017	58.14 %	38.74 %	51.44 %
2018	50.21 %	25.98 %	43.11 %
2019	48.25 %	18.61 %	82.3 %
2020	43.74 %	12.84 %	-55.51 %
2021	30.94 %	12.36 %	13.67 %
2022	34.28 %	12.41 %	-22.21 %
2023	34.26 %	10.89 %	-5.39 %
2024e	34.26 %	13.28 %	14.51 %
2025e	34.26 %	14.21 %	15.17 %

날짜	VIVA Biotech Holdings 주당 매출	VIVA Biotech Holdings EBIT 당 주식	VIVA Biotech Holdings 주당 이익
2025e	1.6 undefined	0 undefined	0.24 undefined
2024e	1.41 undefined	0 undefined	0.21 undefined
2023	1.11 undefined	0.12 undefined	-0.06 undefined
2022	1.24 undefined	0.15 undefined	-0.28 undefined
2021	1.07 undefined	0.13 undefined	0.15 undefined
2020	0.44 undefined	0.06 undefined	-0.25 undefined
2019	0.22 undefined	0.04 undefined	0.18 undefined
2018	0.18 undefined	0.05 undefined	0.08 undefined
2017	0.13 undefined	0.05 undefined	0.07 undefined
2016	0.08 undefined	0.03 undefined	0.02 undefined

	주당 매출	EBIT 당 주식	주당 이익
2016	0.08 CNY	0.03 CNY	0.02 CNY
2017	0.13 CNY	0.05 CNY	0.07 CNY
2018	0.18 CNY	0.05 CNY	0.08 CNY
2019	0.22 CNY	0.04 CNY	0.18 CNY
2020	0.44 CNY	0.06 CNY	-0.25 CNY
2021	1.07 CNY	0.13 CNY	0.15 CNY
2022	1.24 CNY	0.15 CNY	-0.28 CNY
2023	1.11 CNY	0.12 CNY	-0.06 CNY
2024e	1.41 CNY	0 CNY	0.21 CNY
2025e	1.6 CNY	0 CNY	0.24 CNY

	주식 수량
2016	1.15 조. Aktien
2017	1.16 조. Aktien
2018	1.19 조. Aktien
2019	1.48 조. Aktien
2020	1.57 조. Aktien
2021	1.97 조. Aktien
2022	1.92 조. Aktien
2023	1.94 조. Aktien
2024e	1.94 조. Aktien
2025e	1.94 조. Aktien

날짜	VIVA Biotech Holdings 배당금
2021	0.01 undefined
2020	0.03 undefined
2019	0.01 undefined

	배당금	배당금 (추정)
2016	0 CNY	0 CNY
2017	0 CNY	0 CNY
2018	0 CNY	0 CNY
2019	0.01 CNY	0 CNY
2020	0.03 CNY	0 CNY
2021	0.01 CNY	0 CNY
2022	0 CNY	0 CNY
2023	0 CNY	0 CNY
2024e	0 CNY	0 CNY
2025e	0 CNY	0 CNY

날짜	VIVA Biotech Holdings 배당률
2025e	5.21 %
2024e	5.69 %
2023	4.97 %
2022	4.97 %
2021	7.14 %
2020	-13 %
2019	2.79 %
2018	4.97 %
2017	4.97 %
2016	4.97 %

	배당률
2016	4.97 %
2017	4.97 %
2018	4.97 %
2019	2.79 %
2020	-13 %
2021	7.14 %
2022	4.97 %
2023	4.97 %
2024e	5.69 %
2025e	5.21 %

%-지분	이름	주식	변경
16.67049 %	Mao (Chen Cheney)	357,043,527	0
10.22678 %	Wu (John Jiong)	219,034,092	0
7.00355 %	Temasek Holdings Pte. Ltd.	150,000,000	0
6.11913 %	Mao (Jun)	131,057,654	0
4.66904 %	Zhou (Min)	100,000,000	0
3.96868 %	Wang (Stephen Hui)	85,000,000	0
0.99834 %	Wu (Ying)	21,382,127	0
0.69196 %	Ren (Delin)	14,820,248	0
0.55253 %	Dimensional Fund Advisors, L.P.	11,834,000	0
0.13490 %	Norges Bank Investment Management (NBIM)	2,889,337	-372,886
0.06240 %	California Public Employees' Retirement System	1,336,500	58,000
0.06207 %	American Century Investment Management, Inc.	1,329,500	0
0.05526 %	Dimensional Fund Advisors, Ltd.	1,183,500	0
0.03656 %	State Street Global Advisors (US)	783,000	-118,500
0.03217 %	AGF Investments Inc.	688,985	0
0.01289 %	Vident Investment Advisory, LLC	276,000	0
0.01289 %	Exchange Traded Concepts, LLC	276,000	0
0.01273 %	Redwood Wealth Management Group, LLC	272,750	272,750
0.00726 %	China Universal Asset Management Co., Ltd.	155,500	0
0.00416 %	Avantis Investors	89,000	-315,000
0.00245 %	China Asset Management (Hong Kong) Limited	52,500	0
0 %	First Seafront Fund Management Co., Ltd.	0	-105,500
0 %	Andbank Wealth Management, SGIIC, S.A.U.	0	-2,000
0 %	Topsperity Fund Management Co., Ltd.	0	-500
0 %	Ping An Fund Management Company Limited	0	-66,500
0 %	Bank of China Investment Management Co., Ltd.	0	-72,500
0 %	Hwabao WP Fund Management Co., Ltd.	0	-240,000
0 %	GF Fund Management Co., Ltd.	0	-7,084,000
0 %	INVESCO Great Wall Fund Management Co. Ltd.	0	-17,000,000
0 %	Guotai Asset Management Co., Ltd.	0	-562,000
0 %	E Fund Management Co. Ltd.	0	-44,930
0 %	Yinhua Fund Management Co., Ltd.	0	-79,500
0 %	Bosera Asset Management Co., Ltd.	0	-14,079,000
0 %	China Asset Management Co., Ltd.	0	-705,000
0 %	China Southern Asset Management Co. Ltd.	0	-284,500
0 %	Fullgoal Fund Management Co., Ltd.	0	-16,500
0 %	Vanguard Investments Australia Ltd.	0	-48,126
0 %	Penghua Fund Management Co., Ltd.	0	-435,500
0 %	Harvest Fund Management Co., Ltd.	0	-626,500
0 %	Boston Partners	0	-167,000
0 %	The Vanguard Group, Inc.	0	-11,000
0 %	HSBC Global Asset Management (UK) Limited	0	-200,600
0 %	BlackRock Advisors (UK) Limited	0	-2,635,000
0 %	State Street Global Advisors Ireland Limited	0	-244,000
0 %	BlackRock Institutional Trust Company, N.A.	0	-17,254,500
0 %	Nuveen LLC	0	-855,500
0 %	Abaris Investment Management AG	0	-120,000
0 %	Broad Asset Management Co., Ltd	0	-5,599,500
0 %	Vanguard Global Advisers LLC	0	-43,500

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
HBM Holdings	공급업체고객	0,74	0,71	0,17	0,93	0,87
JPMorgan Chase	공급업체고객	0,64	0,74	0,76	0,89	0,54	-0,28
Schrodinger	공급업체고객	0,55	0,78	0,84	0,56	0,94	0,72

What values and corporate philosophy does VIVA Biotech Holdings represent?

VIVA Biotech Holdings represents a commitment to innovation, collaboration, and excellence in the biotechnology industry. As a leading company, VIVA strives to provide high-quality drug discovery services and help clients achieve their research goals. The company's corporate philosophy revolves around customer-centric solutions, where their experienced team utilizes cutting-edge technologies and state-of-the-art facilities to deliver best-in-class services. With a focus on rapid and cost-effective drug development, VIVA Biotech Holdings aims to contribute extensively to the advancement of healthcare and pharmaceutical breakthroughs.

In which countries and regions is VIVA Biotech Holdings primarily present?

VIVA Biotech Holdings is primarily present in China and the United States.

What significant milestones has the company VIVA Biotech Holdings achieved?

VIVA Biotech Holdings has achieved several significant milestones. Firstly, the company successfully listed on the Hong Kong Stock Exchange in 2019, marking an important step in its growth. Additionally, VIVA Biotech has consistently demonstrated its strength in drug discovery services and collaborations. It has established numerous strategic partnerships with leading pharmaceutical companies globally, fueling its reputation as a trusted biotech partner. Moreover, VIVA Biotech has expanded its operations by opening multiple state-of-the-art research centers in China and abroad. These accomplishments highlight VIVA Biotech Holdings' continuous commitment to innovation, partnerships, and global expansion within the biotech industry.

What is the history and background of the company VIVA Biotech Holdings?

VIVA Biotech Holdings is a leading structure-based drug discovery platform established in 2008. The company primarily focuses on enabling and supporting biotechnology and pharmaceutical companies in their drug discovery and development efforts. VIVA Biotech Holdings has a proven track record of success in assisting clients to identify and optimize potential drug candidates. Through its innovative services and expertise, the company has built a strong reputation and has become a trusted partner in the biotech industry. With a commitment to scientific excellence and cutting-edge technology, VIVA Biotech Holdings continues to contribute to advancements in drug discovery, making valuable contributions to the healthcare sector.

Who are the main competitors of VIVA Biotech Holdings in the market?

Some of the main competitors of VIVA Biotech Holdings in the market include Charles River Laboratories, Evotec AG, WuXi AppTec, Eurofins Scientific, and Albany Molecular Research Inc.

In which industries is VIVA Biotech Holdings primarily active?

VIVA Biotech Holdings is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of VIVA Biotech Holdings?

The business model of VIVA Biotech Holdings focuses on providing comprehensive and high-quality drug discovery services to global pharmaceutical and biotechnology companies. VIVA Biotech offers structure-guided drug discovery (SGDD) and other innovative technologies to accelerate the development of potential therapeutics. By leveraging its advanced platform and expertise, VIVA Biotech aims to identify and optimize drug candidates with high success rates. With a strong emphasis on collaboration and efficient processes, the company strives to facilitate the discovery and development of novel drugs, ultimately contributing to advancements in the healthcare industry.

VIVA Biotech Holdings 2024의 P/E 비율은 얼마입니까?

VIVA Biotech Holdings의 P/E 비율은 3.77입니다.

VIVA Biotech Holdings 2024의 KUV는 얼마입니까?

VIVA Biotech Holdings의 P/S 비율은 0.55입니다.

VIVA Biotech Holdings의 AlleAktien 품질 점수는 얼마인가요?

VIVA Biotech Holdings에 대한 AlleAktien 품질 점수는 4/10입니다.

VIVA Biotech Holdings 2024의 매출은 얼마인가요?

예상되는 VIVA Biotech Holdings 매출은 3.03 조. CNY입니다.

VIVA Biotech Holdings 2024의 이익은 얼마인가요?

예상되는 VIVA Biotech Holdings 이익은 439.11 백만 CNY입니다.

VIVA Biotech Holdings은 무엇을 하나요?

VIVA Biotech Holdings is a leading biopharmaceutical company offering a comprehensive range of top-quality services and advanced research tools. The company provides a wide range of solutions to support research and development projects in the field of biology, particularly in the areas of biochemistry, biotechnology, and drug development. The business model of VIVA Biotech Holdings is based on three main divisions: Viva Biotech, Viva Biotech Hutchison, and VivaBioCell. Viva Biotech is a leading service provider for drug discovery and development. The company offers comprehensive biological research services to accelerate drug development, with a focus on the rapid identification of high-quality drug candidates through the use of cutting-edge technology platforms and instruments. Viva Biotech Hutchison is a strategic partnership between the company and Hutchison China MediTech Limited, a leading Chinese biopharmaceutical company. The partnership includes a unique platform for drug discovery and development, securing access to proprietary technologies and instruments. The collaboration enables VIVA Biotech to offer a comprehensive and competitive value chain in drug development. The third division, VivaBioCell, is a specialized laboratory offering primary and cultured human cells. These cells are used in research to understand bioprocesses and develop innovative approaches to treating serious diseases. VivaBioCell enables the provision of high-quality cells in the shortest possible time, providing a competitive advantage. VIVA Biotech Holdings' portfolio includes a wide range of products and services, ranging from chemical molecule modeling to the manufacture of drug candidates. The offerings also include advanced screening approaches, protein production, structural elucidation, in vitro screening, and in vivo animal testing. Viva Biotech's biological research services utilize state-of-the-art technology platforms such as high-throughput screening, protein structural elucidation, and single-cell technology. The company has a network of over 600 customers, including biotechnology and pharmaceutical companies, as well as research institutions in North America, Europe, and Asia. The versatile and scientifically sound expertise of VIVA Biotech Holdings enables the company to develop tailored solutions for customer projects to achieve optimal results. In addition, VIVA Biotech Holdings has its own portfolio of selected drug candidates with potential for clinical success, which are sought after in the pharmaceutical industry. The portfolio consists of eight drug candidates, including two in Phase III clinical trials. VIVA Biotech Holdings' business model is based on extensive biological expertise, cutting-edge technology platforms, and a wide range of products and services to support biology research and development projects. The company specializes in the accelerated discovery of high-quality drug candidates, providing a competitive advantage over other companies in the market.

VIVA Biotech Holdings 배당금은 얼마입니까?

VIVA Biotech Holdings은(는) 연간 번의 배당을 통해 0 CNY의 배당금을 지급합니다.

VIVA Biotech Holdings이 얼마나 자주 배당을 지급하나요?

VIVA Biotech Holdings의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

VIVA Biotech Holdings ISIN이 무엇입니까?

VIVA Biotech Holdings의 ISIN은 KYG9390W1015입니다.

VIVA Biotech Holdings WKN은 무엇인가요?

VIVA Biotech Holdings의 WKN은 A2PH5Q입니다.

VIVA Biotech Holdings 티커는 무엇인가요?

VIVA Biotech Holdings의 티커는 1873.HK입니다.

VIVA Biotech Holdings이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 VIVA Biotech Holdings은(는) 0.01 CNY 의 배당금을 지급했습니다. 이는 약 1.17 %의 배당 수익률에 해당합니다. 향후 12개월 동안 VIVA Biotech Holdings은(는) 0 CNY의 배당금을 지급할 것으로 예상됩니다.

VIVA Biotech Holdings의 배당 수익률은 얼마입니까?

VIVA Biotech Holdings의 현재 배당 수익률은 1.17 %입니다.

VIVA Biotech Holdings의 배당금은 언제 지급되나요?

VIVA Biotech Holdings은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

VIVA Biotech Holdings의 배당금은 얼마나 안전한가요?

VIVA Biotech Holdings은(는) 지난 2년 동안 매년 배당금을 지급했습니다.

VIVA Biotech Holdings의 배당금은 얼마입니까?

향후 12개월 동안 0 CNY의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

VIVA Biotech Holdings이(가) 속해 있는 섹터는 어디인가요?

VIVA Biotech Holdings은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von VIVA Biotech Holdings kaufen, um die vorherige Dividende zu erhalten?

VIVA Biotech Holdings의 마지막 배당금을 0.01 CNY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

VIVA Biotech Holdings의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

VIVA Biotech Holdings의 2023년도 배당금은 얼마였습니까?

2023년에 VIVA Biotech Holdings는 0 CNY를 배당금으로 지급했습니다.

VIVA Biotech Holdings는 어떤 화폐로 배당금을 지급하나요?

VIVA Biotech Holdings의 배당금은 CNY에 지급됩니다.

Scope 1 - 직접 방출	1,404.35
스코프 2 - 구매한 에너지로부터의 간접적인 배출	45,376.9
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량	46,781.2
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율	45.02
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	VIVA Biotech Holdings 티커
프랑크푸르트	VB0.F
HKSE	1873.HK
뮌헨	VB0.MU
PNK	VBIZF

VIVA Biotech Holdings 티커	VIVA Biotech Holdings FIGI
1873:HK	BBG00NZ74JJ9
VBIZF:US	BBG00Q8HRQ63
VBIZF:UV	BBG00Q8HRQN4
VB0:GR	BBG00QJ361Q8
VB0:GF	BBG00QJ361R7
VB0:GS	BBG00QJ361V2
VB0:GM	BBG00QJ361W1
VB0:GB	BBG00QJ361X0
VB0:GZ	BBG00QJ5X0S3
1873EUR:EP	BBG00QJ7BVD1
1873EUR:EZ	BBG00QJ7BVK3
1873EUR:XS	BBG00QJ7BVY8
1873EUR:XH	BBG00QJ7BW12
1873EUR:XF	BBG00QJ7BW30
1873EUR:XE	BBG00QJ7BW58
1873EUR:XJ	BBG00QJ7BW67
1873EUR:XL	BBG00QJ7BW76
1873EUR:XG	BBG00QJ7BW94
1873EUR:XO	BBG00QJ7BWC0
1873EUR:XA	BBG00QJ7BWM9
1873EUR:XT	BBG00QJ7BWR4
1873EUR:XW	BBG00QJ7BWT2
1873EUR:XU	BBG00QJ7BWW8
1873EUR:XV	BBG00QJ7BX01
1873EUR:XM	BBG00QJ7BX29
1873EUR:XQ	BBG00QJ7BX47
1873EUR:XX	BBG00QJ7BX56
1873EUR:XZ	BBG00QJ7BX65
1873EUR:X1	BBG00QJ7BX83
1873EUR:EU	BBG00QJ7BXB9
1873HKD:EP	BBG00QYZ7SK6
1873HKD:EZ	BBG00QYZ7SM4
1873HKD:XS	BBG00QYZ7SN3
1873HKD:X2	BBG00QYZ7SP1
1873HKD:XH	BBG00QYZ7SR9
1873HKD:XF	BBG00QYZ7ST7
1873HKD:XE	BBG00QYZ7SW3
1873HKD:XJ	BBG00QYZ7SX2
1873HKD:XL	BBG00QYZ7SY1
1873HKD:XG	BBG00QYZ7SZ0
1873HKD:XO	BBG00QYZ7T06
1873HKD:XA	BBG00QYZ7T42
1873HKD:E1	BBG00QYZ7T51
1873HKD:XT	BBG00QYZ7T60
1873HKD:XW	BBG00QYZ7T79
1873HKD:XU	BBG00QYZ7T88
1873HKD:XV	BBG00QYZ7TB4
1873HKD:XM	BBG00QYZ7TC3
1873HKD:XQ	BBG00QYZ7TD2
1873HKD:XX	BBG00QYZ7TF0
1873HKD:XZ	BBG00QYZ7TG9
1873HKD:X1	BBG00QYZ7TJ6
1873HKD:EU	BBG00QYZ7TL3
VB0:LA	BBG018H9ST36
VB0:LU	BBG018J3GBV8

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커1873.HK

ISINKYG9390W1015

WKNA2PH5Q

VIVA Biotech Holdings 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

VIVA Biotech Holdings 주가 이력

VIVA Biotech Holdings 주식 매출, EBIT, 이익 KYG9390W1015 · A2PH5Q

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

VIVA Biotech Holdings 매출, 이익 및 EBIT 역사

VIVA Biotech Holdings 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

VIVA Biotech Holdings 주식 마진 KYG9390W1015 · A2PH5Q

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

VIVA Biotech Holdings 마진 역사

VIVA Biotech Holdings 주식 매출, EBIT, 주당 순이익 KYG9390W1015 · A2PH5Q

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

VIVA Biotech Holdings 매출, 이익 및 EBIT 주당 역사

VIVA Biotech Holdings 주식 및 주식 분석

VIVA Biotech Holdings Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

VIVA Biotech Holdings 역사적인 P/E, EBIT 및 P/S에 따른 평가

VIVA Biotech Holdings 주식 수량 KYG9390W1015 · A2PH5Q

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

VIVA Biotech Holdings 주식 배당금 KYG9390W1015 · A2PH5Q

배당금

배당금에 대한 개요

해석 및 사용

투자 전략

VIVA Biotech Holdings 배당금 내역

VIVA Biotech Holdings 주식 배당률 KYG9390W1015 · A2PH5Q

배당비율

연간 배당비율이란 무엇인가요?

데이터 해석 방법

투자에 대한 데이터 사용

VIVA Biotech Holdings 배당금지급률 역사

한눈에 과소평가된 주식을 인식하세요.

티커
1873.HK

ISIN
KYG9390W1015

WKN
A2PH5Q